EFFICACY DATA IN SUBPOPULATIONS

^*After Week 48, an open-label treatment period began where patients initially randomized to TREMFYA® or placebo at Week 0 continued to receive TREMFYA® 100 mg q8w at Week 52 through the extension period. Patients initially randomized to Humira® entered a washout period after their final dose of Humira® at Week 47 and initiated TREMFYA® 100 mg at Week 52 and then q8w thereafter.

^†After Week 48, patients who discontinued study agent due to lack of efficacy or an AE or worsening of psoriasis, or who started a protocol-prohibited medication including conventional and biologic systemic therapy, phototherapy, and/or ultra–high-potency corticosteroids were considered treatment failures. Other topical agents for psoriasis were permitted.

^‡The last dose of TREMFYA® was administered at Week 252; efficacy was evaluated through Week 252.

^§Safety was evaluated through Week 264.

^||At Week 28, patients treated with TREMFYA® achieving PASI 90 (responders) were re-randomized in a 1:1 ratio to continue TREMFYA® 100 mg q8w or placebo. Patients treated with placebo were re-treated with TREMFYA® and received another dose 4 weeks later, then q8w thereafter upon loss of 50% or more of Week 28 PASI response. TREMFYA® nonresponders continued TREMFYA® treatment.

^¶PlaceboTREMFYA® responders received placebo q8w beginning at Week 28. Upon loss of ≥50% Week 28 PASI response, patients were re-treated with TREMFYA®, another dose 4 weeks later, then q8w thereafter. PlaceboTREMFYA® nonresponders at Week 28 continued TREMFYA® q8w.

^#Humira® responders received placebo and upon loss of 50% or more of Week 28 PASI response, initiated TREMFYA®, then received another dose 4 weeks later, then q8w thereafter. Humira® nonresponders initiated TREMFYA® at Week 28, then received another dose 4 weeks later, then q8w thereafter.